OptumRx, a UnitedHealth subsidiary, is tracking three new drugs this year:
- Brensocatib: An oral treatment for noncystic fibrosis bronchiectasis which gained FDA approval Aug. 12. It is the first targeted therapy for the chronic lung condition and has shown reduced exacerbations in clinical trials.
- Tolebrutinib: An oral therapy under FDA review for nonrelapsing secondary progressive multiple sclerosis — which impacts about 15% of patients and has limited treatment options. Tolebrutinib is the first drug to significantly slow disability progression in the population.
- Leqembi SC (lecanemab): A subcutaneous version of Alzheimer’s drug Leqembi pending FDA approval. If approved, it would be the first self-administered treatment in its class.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
